Tissue-Resident Type 2 Innate Lymphoid Cells Arrest Alveolarization in Bronchopulmonary Dysplasia

Figure 3

IL-33 enhanced the number of ILC2s dramatically in the lung of BPD mice. (a) C57BL/6 BPD mice were treated with mouse recombinant IL-33, anti-ST2 antibody, or PBS every alternate day from day 7 after birth. Neonatal mice were euthanized for lungs on P14. (b) Representative hematoxylin-eosin-stained sections of the lung from C57BL/6 mice treated with saline, LPS+vehicle (IgG), LPS+IL-33, and LPS+anti-ST2. Original magnification, ×200. (c) Representative results of ILC2 detected by flow cytometry on different postnatal days in saline, LPS+vehicle, LPS+IL-33, and LPS+anti-ST2 groups. (d) Percentage of ILC2s in the lung on different postnatal days in saline, LPS+vehicle, LPS+IL-33, and LPS+anti-ST2 groups. (e, f) Relative expression of IL-4 and IL-13 in the lung in saline, LPS+vehicle, LPS+IL-33, and LPS+anti-ST2 groups, respectively. (g, h) Representative results of M1 and M2 macrophages detected by flow cytometry in saline, LPS+vehicle, LPS+IL-33, and LPS+anti-ST2 groups, respectively. (i, j) Percentage of M1 and M2 macrophages in the lung in saline, LPS+vehicle, LPS+IL-33, and LPS+anti-ST2 groups, respectively. Data are represented as . . indicates for , indicates , indicates , and indicates .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)